KineMed Announces Biomarker Discovery Collaboration with GSK
KineMed, Inc. enters multi-year agreement with GlaxoSmithKline to develop kinetic biomarkers
Marc Hellerstein, M.D., Ph.D., Chief of the Scientific Advisory Board of KineMed, stated: “Our shared goal with GSK is to identify causal pathways and kinetic signatures that can better inform drug development decisions. The missing links in developing drugs to treat muscle wasting, fibrosis and metabolic diseases have been reliable biomarkers that measure the degree to which we are having therapeutic impact on their underlying disease processes. KineMed’s technology, which measures the dynamics of cellular biochemical networks, is focused on developing better metrics of the disease pathology of those disorders and therefore generates competitive advantage in developing effective drugs against them.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.